DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Bioactive CompoundsBioactive Compounds
  4. /EpigeneticsEpigenetics
  5. /HDACHDAC
  6. /IvaltinostatIvaltinostat
Chemical structure of CAS 936221-33-9

Ivaltinostat

CAS No.936221-33-9
MDL No.MFCD25976805
MFC24H33N3O4
MW427.50
InChI KeyAUGCSOFQTDKPSO-RGVLZGJSSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.936221-33-9
Product NameIvaltinostat

Associated Conditions

neoplasm·pancreatic neoplasm·myelodysplastic syndrome
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.

Scientific reports • Vol. 8, Issue 1 • 2018
PMID: 30068917PMC: PMC6070546DOI: 10.1038/s41598-018-30008-5

CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.

Scientific reports • Vol. 7, Issue 1 • 2017
PMID: 28883618PMC: PMC5589721DOI: 10.1038/s41598-017-11094-3

Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology • Vol. 20, Issue 5 • 2016
PMID: 27610034PMC: PMC5014994DOI: 10.4196/kjpp.2016.20.5.477

Documentation

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact